Tanabe Pharma DUX4 Expression Adjustment Patent EP3950006A1
Summary
Tanabe Pharma Corporation has been granted European Patent EP3950006A1 covering compounds, methods, and pharmaceutical compositions for adjusting DUX4 expression. The patent application was published on April 15, 2026, and names six inventors including Shinji Kumagai and Takayuki Kanagawa. The IPC classifications indicate therapeutic applications in muscular conditions (A61P 21/00) using genetic therapy approaches (C12N 15/113, A61K 48/00). The designated states cover 31 European countries including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.
About this source
GovPing monitors EPO Patent Bulletin - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 53 changes logged to date.
What changed
Tanabe Pharma Corporation has been granted European Patent EP3950006A1 for compounds, methods, and pharmaceutical compositions related to DUX4 expression adjustment. The patent application, published by the EPO on April 15, 2026, names six inventors and carries IPC classifications indicating therapeutic applications for muscular disorders using nucleic acid-based genetic therapy approaches. The patent is designated across 31 European contracting states.
Pharmaceutical and biotechnology companies developing gene therapy products targeting DUX4 or similar genetic expression targets should conduct freedom-to-operate analyses. Competitors with overlapping technology may need to evaluate licensing options or design-around strategies. Research institutions studying muscular dystrophy or facioscapulohumeral muscular dystrophy (FSHD) specifically may find this patent relevant to their commercialization pathways.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR DUX4 EXPRESSION ADJUSTMENT
Publication EP3950006A1 Kind: A1 Apr 15, 2026
Applicants
Tanabe Pharma Corporation
Inventors
KUMAGAI, Shinji, YASHIRO, Takashi, ARAKI, Tomo, KANAGAWA, Takayuki, OKAGAKI, Chieko, FURUKAWA, Hiroyuki
IPC Classifications
A61K 48/00 20060101AFI20240508BHEP A61P 21/00 20060101ALI20240508BHEP A61P 43/00 20060101ALI20240508BHEP C12N 15/113 20100101ALI20240508BHEP A61K 31/7088 20060101ALI20240508BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.